Alqalam Journal of Medical and Applied Sciences. 2026;9(8):2380-2387
https://doi.org/10.54361/ajmas.269809

Review article

Hemostatic Role of Local Anesthetic Techniques in Major Orthopedic Joint Surgery: Mechanisms, Adjuvants, and Clinical Applications. A Narrative Review

Rabe Altomi*[1], Mesad Ghula[1], Ayoub Dhu[1], Abdulwhab Almahroug[1], Fadia Oshkondale[2]

[1]*Academic Surgical Department, Faculty of Medicine, University of Zawia, Libya*
[2]*Pharmacological Department, Faculty of Medicine, University of Zawia, Libya*
Corresponding author: *r.altomi@zu.edu.ly*

Abstract
Intraoperative joint bleeding during major orthopedic surgeries, particularly total joint arthroplasty (TJA) and arthroscopic procedures, represents a clinically significant challenge that prolongs operative time, obscures the surgical field, and increases the risk of postoperative complications, including hematoma and the need for blood transfusion. Although systemic antifibrinolytics such as intravenous Tranexamic acid (TXA) remain the standard of care, local anesthetic (LA) techniques are increasingly recognized for their direct modulatory effects on surgical site microvasculature. This narrative review examines the pharmacological mechanisms, comparative hemostatic profiles, and synergistic potential of key local anesthetic delivery techniques, including Local Infiltration Analgesia (LIA), peripheral nerve blocks (PNBs), neuraxial anesthesia, and intra-articular injections, in reducing intraoperative joint bleeding.
Keywords: Local Anesthesia, Intraoperative Hemostasis, Total Joint Arthroplasty, Ropivacaine, Local Infiltration Analgesia.

Introduction

Modern orthopedic surgery relies heavily on intraoperative blood management, particularly in high volume subspecialties such as advanced arthroscopy and total joint arthroplasty (TJA). The rich periarticular vascular network is frequently compromised by the structural demands of bone resection, synovectomy, and capsular release, resulting in significant intraoperative blood loss that may range from 200 mL to over 1,500 mL in major arthroplasty procedures [1–3]. Surgeons have traditionally relied primarily on mechanical tourniquets to maintain a bloodless surgical field; however, prolonged tourniquet inflation is associated with complications including post-ischemic reperfusion injury, severe thigh pain, neuromuscular damage, and accelerated postoperative fibrinolysis [3].

Consequently, multimodal blood management paradigms that promote hemodynamic stability while directly controlling local bleeding cascades have become increasingly prevalent in contemporary orthopedic practice. Systemically administered anti-fibrinolytic, particularly intravenous Tranexamic acid (TXA), have contributed substantially to the reduction of transfusion rates worldwide [4]. In parallel, local and regional anesthetic techniques have emerged as complementary components of microvascular management. Contemporary local anesthesia protocols including Local Infiltration Analgesia, targeted peripheral nerve blocks (PNBs), and intra-articular multi drug formulations exert important, predictable physiological effects on joint microvasculature while simultaneously providing superior perioperative analgesia and reducing opioid consumption [5].

Despite their growing adoption, the hemostatic mechanisms of local anesthetic techniques remain incompletely characterized in the orthopedic literature, and no unified protocol has been universally validated. This narrative review addresses this gap by systematically examining the pharmacological basis of LA-mediated hemostasis, comparing the blood-sparing profiles of key delivery modalities, evaluating the evidence for adjuvant combinations, and synthesizing clinical guidance for practicing orthopedic surgeons and anesthesiologists. This narrative review examines the pharmacological mechanisms, comparative hemostatic profiles, and synergistic potential of key local anesthetic delivery techniques including Local Infiltration Analgesia (LIA), peripheral nerve blocks (PNBs), neuraxial anesthesia, and intra-articular injections in reducing intraoperative joint bleeding.

Pharmacological Mechanisms of Local Anesthetics on Vascular Tone

The influence of local anesthetics (LAs) on periarticular hemorrhage is largely determined by their direct, concentration-dependent modulation of vascular smooth muscle tone. Although the primary therapeutic objective of LAs is to block voltage-gated sodium channels on neuronal membranes to inhibit nociceptive transmission, these agents readily diffuse across tissue barriers to interact with the peripheral microvasculature. Understanding this dual action is essential to appreciating their hemostatic utility in the orthopedic setting.

The Biphasic Vascular Response

Local anesthetics exhibit a well-characterized, concentration-dependent biphasic effect on the surrounding vasculature. At low, clinically relevant concentrations, most LAs induce localized vasoconstriction through two complementary mechanisms: an initial release of intracellular calcium from the sarcoplasmic reticulum of vascular smooth muscle cells, followed by inhibition of endothelial nitric oxide synthase (eNOS), which transiently attenuates vasodilator signaling.

Received: *01-06-2026 - **Accepted:** 29-07-2026 - **Published:** 05-08-2026*

Conversely, at high or toxic concentrations, LAs block voltage-gated L-type calcium channels on the vascular smooth muscle membrane, preventing the influx of extracellular calcium required to sustain basal vascular tone, thereby producing significant vasodilation. This biphasic dose-response relationship has important clinical implications: maintaining LAs within the therapeutic window is not only a safety requirement but also a prerequisite for achieving the desired vasoconstrictive hemostatic effect.

Agent Specific Properties: Lidocaine, Bupivacaine, and Ropivacaine

In clinical practice, the choice of local anesthetic significantly influences the baseline bleeding profile at the surgical site, owing to structural differences among amide-type agents. At standard surgical doses, lidocaine acts as a potent vasodilator that rapidly attenuates vascular smooth muscle contraction; accordingly, when administered without a supplementary vasoconstrictor, it may enhance microvascular leakage [1]. Bupivacaine exhibits less pronounced vasodilator effects than lidocaine and gradually relaxes larger arterioles, producing a mild to moderate vasodilator response. Because Bupivacaine is generally vasodilator at clinical concentrations, adjunctive vasoconstrictors are necessary to prevent hyperperfusion at the surgical site. In contrast, Ropivacaine demonstrates intrinsic vasoconstrictive properties on small cutaneous and muscular capillaries through selective inhibition of calcium channels on sensory nerve fibers, thereby actively reducing local blood flow. This unique hemostatic profile renders Ropivacaine the preferred agent for blood-sparing LIA protocols [1]. Levobupivacaine, the S-enantiomer of bupivacaine, also exhibits a mild vasoconstrictive profile intermediate between bupivacaine and Ropivacaine, and represents a viable alternative where Ropivacaine is unavailable.

Table 1 provides a comparative summary of the vascular effects, clinical properties, and preferred applications of the most commonly used amide-type local anesthetics in orthopedic joint surgery.

Table 1. Comparative vascular properties and clinical applications of amide-type local anesthetic agents in orthopedic joint surgery.

Agent	Vascular Effect	Mechanism	Onset	Duration	Preferred Use
Lidocaine	Vasodilator (dose-dependent)	Na^+ channel block; mild Ca^{2+} inhibition	Fast (2–5 min)	Short (1–2 h)	Diagnostic blocks; short procedures
Bupivacaine	Mild-moderate vasodilator	Na^+ channel block; arteriolar relaxation	Moderate (5–10 min)	Long (4–8 h)	Requires epinephrine adjunct for hemostasis
Ropivacaine	Intrinsic vasoconstrictor	Selective sensory Na^+ block; Ca^{2+} channel inhibition on capillaries	Moderate (5–10 min)	Long (4–8 h)	Preferred for blood-sparing LIA protocols
Levobupivacaine	Mild vasoconstrictor	S-enantiomer; intermediate vascular profile	Moderate	Long (4–8 h)	Alternative to ropivacaine where available

LIA = Local Infiltration Analgesia; TKA = Total Knee Arthroplasty; THA = Total Hip Arthroplasty; PAD = Peripheral Artery Disease.



Figure 1: Mechanism of the vasodilator effect of lidocaine illustrating Na⁺channel blockade and downstream vascular smooth muscle relaxation [6].

Received*: 01-06-2026 -* ***Accepted****: 29-07-2026 -* ***Published****: 05-08-2026*

Comparative Analysis of Local Anesthesia Techniques

Various local and regional anesthetic delivery modalities modify the intraoperative bleeding profile through distinct macro- and micro-hemodynamic pathways. Table 3 (see Section 5) provides a side-by-side comparison of these techniques. The following subsections examine the mechanisms and clinical evidence underlying each approach.

Local Infiltration Analgesia (LIA)

Local infiltration analgesia involves the meticulous intraoperative injection of a high volume, diluted local anesthetic solution into the periarticular soft tissues, including the joint capsule, collateral ligaments, and subcutaneous layers, during joint replacement surgery [1]. From a hemostatic perspective, LIA exerts its effects through three complementary mechanisms. First, the localized interstitial hydrostatic pressure generated by the injected fluid volume mechanically compresses small capillaries and venules, producing immediate tamponade of low-pressure bleeding points. Second, direct exposure of the microvasculature to the local anesthetic alters capillary tone through the pharmacological mechanisms described in Section 3. Third, because LIA maps directly to the surgical dissection planes, its vascular modifying effects are concentrated precisely at the sites of greatest tissue injury, an advantage not shared by systemic hemostatic agents [2].

Clinical evidence supporting LIA in blood management continues to grow. A meta-analysis by Lapidus et al. [7] demonstrated that periarticular injection combining Ropivacaine, epinephrine, and ketorolac significantly reduced intraoperative and postoperative blood loss in total knee arthroplasty compared with controls, without increasing complication rates. The blood sparing advantage of LIA is further amplified when the cocktail incorporates intra-articular TXA, as discussed in Section 5.

Peripheral Nerve Blocks (PNBs) and Regional Anesthesia

Peripheral nerve blocks such as adductor canal, femoral, or sciatic nerve blocks and neuraxial anesthesia techniques (spinal and epidural blocks) modify intraoperative bleeding through systemic and regional neural pathways rather than through direct tissue contact [8]. By interrupting afferent nociceptive pathways, regional blockades attenuate the surgical stress response, reducing the reflex release of endogenous catecholamines from the sympathetic nervous system. This sympatholytic effect prevents intraoperative elevations in systemic blood pressure and heart rate that typically exacerbate microvascular bleeding at bone cut sites. By maintaining a stable, controlled mean arterial pressure (MAP), regional blocks reduce the hydrostatic driving pressure behind arterial microbleeding. Additionally, spinal anesthesia induces peripheral vasodilation in the lower extremities and reduces central venous pressure (CVP), thereby diminishing venous engorgement and reducing venous pooling and hemorrhage during surgery.

A recent systematic review and meta-analysis comparing regional (neuraxial) and general anesthesia in Total Knee Replacement (TKR) reported that neuraxial anesthesia was associated with a significantly lower requirement for perioperative blood transfusion compared with general anesthesia. These findings support the potential hemostatic benefits of neuraxial techniques, which may extend beyond analgesia through attenuation of sympathetic activity and modulation of perioperative blood loss [9].

Intra-Articular Injections

Intra articular administration delivers local anesthetics directly into the joint cavity and is commonly employed in minimally invasive procedures such as knee and shoulder arthroscopy. This approach produces hemostasis primarily by increasing the pressure profile within the joint capsule: as intra articular fluid volume increases, exposed synovial vessels undergo mechanical compression [10]. Because the anesthetic solution is contained within the joint space, systemic absorption is slowed, thereby prolonging local vasoconstrictive effects while maintaining a favorable safety profile against local anesthetic systemic toxicity (LAST). Importantly, however, the choice of agent is critical: prolonged intra articular exposure to bupivacaine has been associated with chondrolysis in in vitro and case series evidence, whereas Ropivacaine and Levobupivacaine demonstrate superior chondroprotective profiles [10, 11].

Synergistic Effects of Adjuvants in Local Anesthesia Cocktails

In contemporary orthopedic protocols, standalone local anesthetics are seldom employed in isolation. Rather, LAs are systematically combined with synergistic vasoactive and antifibrinolytic agents in multi-drug formulations commonly referred to as cocktails specifically designed to maximize blood sparing efficacy. The rationale for combination therapy rests on the principle that each adjuvant targets a distinct step in the hemostatic cascade, producing effects that are additive or synergistic rather than merely cumulative [12].

Epinephrine (Adrenaline)

Epinephrine remains the most potent and widely used vasoactive adjuvant in local infiltration. When incorporated into local anesthetic formulations at concentrations of 1:200,000 to 1:400,000, it acts as a powerful alpha-1 adrenergic receptor agonist, inducing rapid and intense contraction of local arterioles and capillaries, thereby substantially reducing microvascular blood flow at the surgical site [13]. The resulting reduction in local tissue perfusion pressure also slows systemic absorption of the local anesthetic, thereby prolonging its duration of action and reducing the risk of systemic

Received: *01-06-2026 -* ***Accepted:*** *29-07-2026 -* ***Published:*** *05-08-2026*

toxicity a dual hemostatic and pharmacokinetic advantage. Epinephrine should, however, be used with caution in patients with severe peripheral artery disease, poorly controlled hypertension, or significant cardiac dysrhythmias, given its systemic adrenergic effects at higher absorbed doses.

Tranexamic Acid (TXA)

The incorporation of TXA into local infiltration analgesia protocols via topical or intra articular administration represents a significant advance in multimodal blood management [4, 3]. TXA, a synthetic lysine analogue, inhibits fibrinolysis by competitively blocking the lysine binding sites on plasminogen molecules, thereby preventing their conversion to plasmin and the subsequent proteolytic degradation of fibrin clots. When administered locally in conjunction with a local anesthetic at the surgical site, TXA stabilizes nascent micro clots forming at the margins of resected bone and soft tissue [14, 3].
Network meta-analyses consistently demonstrate that topical intra articular TXA combined with local anesthetic infiltration reduces total perioperative blood loss and transfusion events compared with standalone systemic or local protocols, without increasing the incidence of deep vein thrombosis or pulmonary embolism a particularly important safety advantage in elderly orthopedic patients with baseline thromboembolic risk factors [15]. The optimal local dose of TXA in Total Joint Arthroplasty (TJA) has been reported in the range of 500 mg to 1 g, although dosing protocols vary across institutions and patient populations.

Corticosteroids and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Local anesthetic formulations frequently incorporate NSAIDs (e.g., ketorolac) and glucocorticoids (e.g., methylprednisolone or dexamethasone) to suppress the immediate post-traumatic inflammatory cascade. These agents inhibit cyclooxygenase (COX) pathways and reduce the synthesis of inflammatory prostanoids, thereby preventing hyperemic vasodilation the reactive increase in blood flow that normally follows surgical tissue injury. This attenuation of the hyperemic response stabilizes local microvascular tone and reduces delayed, post incisional joint oozing [3]. Furthermore, corticosteroids such as dexamethasone have been shown to potentiate and prolong the duration of peripheral nerve block when added to LA cocktails, an additional perioperative benefit beyond hemostasis [12]. Table 2 summarizes the pharmacological class, hemostatic mechanism, route of administration, and key supporting evidence for each major adjuvant class used in LA cocktails for orthopedic joint surgery.

Table 2. Summary of vasoactive and antifibrinolytic adjuvants used in local anesthetic cocktails for major joint surgery.

Adjuvant	Class	Hemostatic Mechanism	Route in TJA	Key Evidence
Epinephrine	α1-adrenergic agonist	Intense arteriolar and capillary vasoconstriction	Intra-articular / LIA (1:200,000)	Reduces intraoperative blood loss; avoid in PAD patients (Gasteiger et al., 2026)
Tranexamic Acid	Antifibrinolytic (lysine analogue)	Blocks plasminogen activation; stabilizes fibrin clots	Intra-articular / topical	Reduces total blood loss and transfusion rate vs. systemic-only protocols; no thromboembolic increase (Wei et al., 2024; NGC, 2020a)
Ketorolac	NSAID (COX inhibitor)	Reduces prostanoid-driven hyperemic vasodilation	Intra-articular	Attenuates post-incisional joint oozing (Wei et al., 2024)
Dexamethasone	Glucocorticoid	Suppresses inflammatory mediators; reduces hyperemic vasodilation	Intra-articular / systemic	Prolongs nerve block duration; reduces swelling-related oozing (Martin et al., 2023)
Methylprednisolone	Glucocorticoid	Potent anti-inflammatory; COX pathway suppression	Intra-articular	Reduces early postoperative joint oozing (Wei et al., 2024)

TJA = Total Joint Arthroplasty; LIA = Local Infiltration Analgesia; TXA = Tranexamic Acid; NSAID = Non-Steroidal Anti-Inflammatory Drug; COX = Cyclooxygenase; PAD = Peripheral Artery Disease; NGC = National Guideline Centre.

Received*: 01-06-2026 -* ***Accepted****: 29-07-2026 -* ***Published****: 05-08-2026*



Figure 2: Proposed multimodal mechanism by which LA cocktail components target successive steps in the intraoperative hemostatic cascade. Each adjuvant addresses a distinct phase: vasoconstriction (epinephrine), antifibrinolysis (TXA), and anti-inflammatory stabilization (NSAIDs/corticosteroids). [2, 3].

Clinical Implications: A Structured Intraoperative Protocol

Translating the pharmacological and mechanistic evidence reviewed above into a safe, reproducible surgical protocol requires attention to timing, anatomical targeting, and dose optimization. The following framework is organized according to operative phases and represents a synthesis of current evidence and clinical guidelines [1, 13, 14, and 15].

Pre-Surgical Cocktail Preparation

A standardized multimodal mixture should be freshly prepared prior to each procedure. A validated, high-volume formulation typically comprises Ropivacaine 200–300 mg selected for its intrinsic vasoconstrictive properties combined with epinephrine 0.5 mg (1:200,000 dilution) to promote sustained local hemostasis, and Tranexamic acid 500 mg – 1 g to inhibit early fibrinolytic activity. Where indicated, ketorolac 15–30 mg may be added to attenuate the hyperemic inflammatory response. The total volume is typically diluted to 100–150 mL with normal saline to achieve adequate tissue distribution [1, 14, and 15].

Deep Capsular Infiltration (Post Exposure, Pre Bone Incision)

Following surgical exposure but prior to bone incision, the deep periarticular tissues should be methodically infiltrated. Needle placement should target periosteal insertions, collateral ligaments, and the posterior capsule, addressing the principal articular branches of the circumflex or genicular arterial systems before they are transected. Ultrasound guidance, where available, improves the accuracy of deep tissue infiltration and reduces the risk of inadvertent intravascular injection [13].

Intermediary Soft Tissue Infiltration (Pre-Trialing)

During bone preparation and trial component insertion, the remaining soft tissue planes including the quadriceps tendon, extensor mechanism, and subsynovial fat pads should be infiltrated with the residual solution. Particular attention should be directed to areas prone to microvascular oozing to maintain clear visibility during press fit component seating or cementing [1, 16].

Superficial Closure Infiltration

The final portion of the cocktail should be injected into the deep subcutaneous layer and dermal margins during wound closure. This step reduces dermal edge bleeding, inhibits superficial nociceptors, and prevents the development of postoperative tracking hematomas [2].

Table 3 provides a structured comparison of the major local anesthetic delivery techniques in terms of their hemostatic pathway, target procedure, blood loss reduction profile, key limitations, and level of supporting evidence.

Table 3. Comparative summary of local anesthetic delivery techniques for intraoperative hemostasis in major joint surgery.

Technique	Hemostatic Pathway	Target Procedure	Blood Loss Reduction	Key Limitations	Evidence Level
LIA	Direct vasoconstriction + hydrostatic compression	TKA / THA	Moderate–High	High volume; LAST risk with incorrect dosing	Level II–III
PNBs	Sympatholysis → MAP reduction → reduced microvascular pressure	TKA / THA / Shoulder arthroplasty	Moderate	Requires skilled operator; motor block side-effects	Level I–II

Received: *01-06-2026 -* ***Accepted:*** *29-07-2026 -* ***Published:*** *05-08-2026*

Spinal / Epidural	CVP reduction + peripheral vasodilation	TKA / THA	Moderate–High	Hypotension risk; contraindicated in coagulopathy	Level I
Intra-Articular Injection	Capsular pressure increase + direct vascular compression	Knee / Shoulder arthroscopy	Low–Moderate	Chondrotoxicity risk (bupivacaine); limited duration	Level II–III
Combined (LIA + PNB + TXA)	Multimodal: direct + neural + antifibrinolytic	TKA / THA (major arthroplasty)	High (synergistic)	Protocol complexity; cost; team coordination	Level I–II

LIA = Local Infiltration Analgesia; PNBs = Peripheral Nerve Blocks; TKA = Total Knee Arthroplasty; THA = Total Hip Arthroplasty; CVP = Central Venous Pressure; MAP = Mean Arterial Pressure; TXA = Tranexamic Acid. Evidence levels according to Oxford Centre for Evidence-Based Medicine (OCEBM) criteria.

Safety Considerations and Complication Avoidance

Although local anesthetic techniques offer significant hemostatic and analgesic benefits, their safe clinical integration requires thorough understanding of the potential risk landscape. Large joints possess extensive circulatory networks that can accelerate systemic absorption, particularly when high volume LIA protocols are employed. Clinicians must strictly adhere to weight-based maximum dose guidelines (e.g., ≤3 mg/kg for Ropivacaine; ≤2 mg/kg for bupivacaine). Should symptoms of local anesthetic systemic toxicity (LAST) including perioral numbness, tinnitus, metallic taste, or altered mental status, occur, the injection must be discontinued immediately and a 20% intravenous lipid emulsion rescue protocol should be initiated without delay [5].

Chondrotoxicity represents a distinct and well-documented safety concern in the arthroscopic setting. Prolonged intra articular exposure to bupivacaine in particular has been demonstrated to cause chondrolysis in both in vitro cell culture models and clinical case series. While this risk is of lesser concern in total joint replacement where the articular cartilage is excised, it is a critical consideration in diagnostic and therapeutic arthroscopy where cartilage preservation is paramount. In such procedures, Ropivacaine or Levobupivacaine at appropriately diluted concentrations should be preferred [10, 11].

The use of potent vasoconstrictors such as epinephrine warrants particular caution in patients with severe peripheral artery disease (PAD) compromised local microcirculation, or prior digital or end-arterial surgery. In these populations, the vasoconstrictive action of epinephrine may precipitate ischemia in tissues with limited collateral supply. A thorough preoperative vascular assessment and individualized risk benefit analysis is essential before including epinephrine in the LA formulation for high risk patients.

The findings of this narrative review converge on a consistent theme: local anesthetic techniques, when thoughtfully selected and strategically deployed, exert clinically meaningful and mechanistically well supported hemostatic effects during major joint surgery. This conclusion is supported by evidence across multiple levels from in vitro pharmacological studies characterizing the vascular smooth muscle effects of individual agents, to prospective clinical trials and network meta-analyses demonstrating reductions in measurable blood loss endpoints, a pattern reaffirmed by recent retrospective evidence on Tranexamic acid administration in total knee arthroplasty [18].

A key interpretive consideration is the distinction between the hemostatic contributions of different technique categories. LIA and intra articular injections act primarily through local pharmacological and mechanical mechanisms at the tissue level, whereas PNBs and neuraxial anesthesia reduce bleeding indirectly through systemic sympatholytic and mean arterial pressure (MAP) reduction.

These two pathways are physiologically distinct and, importantly, non-redundant: combining a direct action technique (LIA) with a systemic acting technique (spinal anesthesia or PNBs) may therefore produce superior hemostatic outcomes compared with either technique alone an inference supported by the growing evidence base for multimodal anesthesia protocols in Total Joint Arthroplasty (TJA), including recent findings that combining local infiltration with Tranexamic acid confers additional blood sparing benefit beyond either measure alone [17].

The adjuvant literature similarly supports a layered approach. Epinephrine, TXA, and anti-inflammatory agents each target different nodes in the hemostatic cascade vasoconstriction, fibrin preservation, and hyperemia attenuation, respectively. Their concurrent use in a structured cocktail is therefore pharmacologically rational and clinically substantiated, provided that patient specific contraindications are carefully considered, a caveat reinforced by recent data indicating that TXA can be used safely even in arthroplasty patients with a prior history of venous thromboembolism once surgeon selection bias is accounted for [19].

It is important to acknowledge, however, that the current evidence base has notable limitations. Considerable heterogeneity exists across published trials in terms of LA agent selection, cocktail composition, injection timing, volume, and blood loss measurement methodology. This heterogeneity complicates direct between study comparisons and limits the derivation of universal dosing recommendations. Furthermore, most high quality evidence derives from elective Total Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA) populations; the hemostatic applicability of these findings to revision arthroplasty, arthroscopic procedures, and pediatric or high comorbidity populations remains less well established and warrants dedicated investigation, although emerging evidence suggests that Tranexamic acid remains safe and effective across nearly all arthroplasty patient subgroups, including those undergoing revision procedures [20].

Received*: 01-06-2026 -* ***Accepted****: 29-07-2026 -* ***Published****: 05-08-2026*

From a practical standpoint, the adoption of structured, protocol-driven LA hemostatic techniques also carries implications for institutional resource allocation and team training. Ultrasound-guided nerve blocks require specialized equipment and procedural competence; multi-drug cocktail preparation requires pharmacy oversight to ensure sterility and compatibility. These implementation considerations should be factored into departmental protocol development and surgical team education.

Conclusion

Local anesthetic techniques represent clinically valuable and evidence-supported adjuncts to systemic hemostatic agents in the management of intraoperative joint bleeding during major orthopedic procedures. By harnessing the intrinsic vasoconstrictive properties of selected agents particularly Ropivacaine and combining them with targeted adjuvants such as Tranexamic acid and epinephrine, multimodal LA protocols deliver robust, site-specific hemostasis directly to the surgical field. Regional anesthetic modalities further contribute by attenuating the surgical stress response and reducing systemic MAP, producing complementary, non-redundant hemostatic effects that enhance the efficacy of local tissue-level interventions. A notable limitation of the present review is its narrative scope and the inherent heterogeneity of the underlying literature; a formal systematic review or meta-analysis with pre specified endpoints would provide a higher level of evidence synthesis. Future research should prioritize prospective, randomized head-to-head comparisons of individual LA techniques and cocktail compositions with standardized blood loss endpoints and patient reported outcomes. The continued refinement of LA formulations, the standardization of intraoperative delivery protocols, and the broader adoption of ultrasound-guided techniques will further consolidate these approaches as essential components of advanced, multimodal orthopedic blood conservation programs.

Funding: This research received no external funding.

Conflict of Interest: The authors declare no conflict of interest.

Ethics Statement: Not applicable. This article is a narrative review of published literature and did not involve human participants or animal subjects.

References

1. Ftaita S, Pagnano M, Thienpont E. The perioperative management of partial knee arthroplasty: Anesthesia, pain management, and blood loss. *Partial Knee Arthroplasty*. 2018:11–8.
2. King GA, Le A, Nickol M, Sarkis B, van der Merwe JM. Periarticular infiltration used in total joint replacements: an update and review article. *J Orthop Surg Res*. 2023;18(1):859. https://doi.org/10.1186/s13018-023-04333-z
3. Wei Z, Yu M, Xu Y, Weng X, Feng B. Impact of intraosseous regional administration of tranexamic acid in total knee arthroplasty on perioperative blood loss: A protocol for a randomized controlled trial. *BMJ Open*. 2024;14(2):e077393.
4. Studzińska D, Pabjańczyk I, Polok K, Szczeklik W. Perioperative utilization of tranexamic acid in total knee and hip arthroplasty procedures in Poland: A survey-based study. *Anaesthesiol Intensive Ther*. 2024;56(3):206–7.
5. Kamel I, Ahmed MF, Sethi A. Regional anesthesia for orthopedic procedures: What orthopedic surgeons need to know. *World J Orthop*. 2022;13(1):11–35.
6. Ueda M, Hirayama Y, Ogawa H, Nomura T, Terashi H, Sakakibara S. Vasodilating effects of antispasmodic agents and their cytotoxicity in vascular smooth muscle cells and endothelial cells: Potential application in microsurgery. *Int J Mol Sci*. 2023;24(13):10850.
7. Lapidus O, Baekkevold M, Rotzius P, Lapidus L, Eriksson K. Preoperative administration of local infiltration anaesthesia decreases perioperative blood loss during total knee arthroplasty – a randomised controlled trial. *J Exp Orthop*. 2022;9. https://doi.org/10.1186/s40634-022-00552-1
8. Ahmed HS, Jayaram PR. Anesthetic considerations for joint replacement surgery in hemophilic arthropathy: A comprehensive review. *Anesth Pain Med*. 2024;19(3):194–208.
9. Elsenosy AM, Hassan E, Yousef AS, Al-Alawi M, Elbagory W, Yousef Jr A. Impact of regional versus general anaesthesia on outcomes following total knee replacement: A systematic review and meta-analysis. *Cureus*. 2025;17(10).
10. Pirri C, Sorbino A, Manocchio N, Pirri N, Devito A, Foti C, Migliore A. Chondrotoxicity of intra-articular injection treatment: A scoping review. *Int J Mol Sci*. 2024;25(13):7010. https://doi.org/10.3390/ijms25137010
11. Vrachnis I, Gliatis J, Papachristou D, Sourouni S, Kouzelis A, Panagopoulos A, Tyllianakis M. The in vivo chondrotoxicity of single intra-articular injection of local anesthetic in rat cartilage. *Cureus*. 2024;16(1):e53103. https://doi.org/10.7759/cureus.53103
12. Martin MF, Lopez SA, Alvarez-Santullano CA. Role of adjuvants in regional anesthesia: A systematic review. *Rev Esp Anestesiol Reanim (Engl Ed)*. 2023;70(2):97–107.
13. Gasteiger L, Lirk P, Marhofer P, Gasteiger E, Hollmann MW, Stundner O. Is it time to reassess local anesthetic and adjuvant mixtures? A narrative review of practice, evidence, and risks. *Anesthesiology*. 2026;144(1):177–90.
14. Cam N. The effect of local tranexamic acid administration on blood loss and transfusion in total knee arthroplasty: A retrospective study. *Med Bull Sisli Etfal Hosp*. 2023;57(2):246–7.
15. National Guideline Centre (NGC). Evidence review for tranexamic acid to minimize blood loss. *NICE*. 2020a.
16. National Guideline Centre (NGC). Evidence review for anaesthesia for knee replacement. *NICE*. 2020b.
17. Wiktor Ł, Osadnik B, Damps M. Can local infiltration analgesia supplemented with tranexamic acid reduce blood loss during total knee arthroplasty? *BMC Musculoskelet Disord*. 2024;25:337. https://doi.org/10.1186/s12891-024-07451-9

Received: *01-06-2026 -* ***Accepted:*** *29-07-2026 -* ***Published:*** *05-08-2026*

18. Liangliang L, Wei H, Tao Z, Pin P, Lianying H. Efficacy and safety of tranexamic acid in reducing hidden blood loss during unilateral total knee arthroplasty: A retrospective study. *Front Med*. 2025;12:1552893. https://doi.org/10.3389/fmed.2025.1552893
19. Palmer RC, Telang SS, Wier J, Dobitsch A, Griffith KM, Lieberman JR, et al. Tranexamic acid is safe in arthroplasty patients who have a history of venous thromboembolism: An analysis accounting for surgeon selection bias. *J Arthroplasty*. 2025;40:1492–9.e1. https://doi.org/10.1016/j.arth.2024.11.011
20. Fillingham YA, Hannon CP, Rainey JP, et al. Tranexamic acid is safe and effective in reducing blood loss and transfusion rates in nearly all patients undergoing total hip and knee arthroplasty. *Arthroplasty Today*. 2025;38:101868. https://doi.org/10.1016/j.artd.2025.101868

Received*: 01-06-2026 -* ***Accepted****: 29-07-2026 -* ***Published****: 05-08-2026*